Prior to its acquisition by J&J, Omrix Biopharmaceuticals developed, manufactured, and marketed biological products for the biosurgical and immunotherapy markets.

The company was initially listed on NASDAQ prior to the acquisition by J&J.

Company: Omrix
Fund: alpinvest
Status: Realized
Team member: Harrold van Barlingen
Technology: Therapeutics